Congress Materials – European Congress of Rheumatology (EULAR 2025)
2025 European Congress of Rheumatology | Jun 11-14 | Barcelona, Spain
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Assessment of Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions with Nipocalimab and Relevance to Patients with Rheumatic Diseases
Di Bei, Jia Zhou, An Vermeulen, Weirong Wang, Jocelyn H. Leu
This document will be available on June 11 2025
Biological Sex-Related Differences in Radiographic Progression and Relationship with Early Clinical Response: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Biologic-Naive Participants with Active Psoriatic Arthritis Treated with Guselkumab
Dafna D. Gladman, Lihi Eder, Carlo Selmi, Philip J. Mease, Alexis Ogdie, Karissa Lozenski, Mohamed Sharaf, Emmanouil Rampakakis, Laura Pina Vegas, Laura C. Coates
This document will be available on June 11 2025
Effect of Gender and Follow-up Time in Damage Accrual: Data from a Latin America Lupus Cohort
Diana Fernandez, Rosana Quintana, Karen Roberts, Romina Nieto, Marina Scolnik, Carmen Funes Soaje, Cintia Otaduy, Verónica Saurit, Valeria Arturi, Guillermo A. Berbotto, Maria Constanza Bertolaccini, Eduardo Mario Kerzberg, María de los Angéles Gargiulo, Cecilia Nora Pisoni, Ana Carolina Ralle, Joaquín Martinez Serventi, Ana Carolina O. S. Montandon, Odirlei Andre Monticielo, Henrique Ataide Mariz, Laíssa Cristina Alves Alvino, Eduardo F. Borba, Emily Figueiredo Neves Yuki, Edgard Torres dos Reis-Neto, Iris Guerra Herrera, Milena Mimica, Gustavo Aroca Martínez, Antonio Iglesias Gamarra, Carlos A. Cañas, Gerardo Quintana-Lopez, Carlos Enrique Toro Gutiérrez, Mario Javier Moreno Alvarez, Olga Lidia Vera-Lastra, Margarita Portela Hernández, Hilda Fragoso-Loyo, Luis H. Silveira, Yelitza C. González-Bello, Carlos Abud-Mendoza, Jorge A. Esquivel Valerio, Marcelo Barrios, Lourdes Carolina Vázquez, Magaly Alva Linares, Manuel F. Ugarte-Gil, Armando Calvo Quiroz, Roberto Muñoz Louis, Ana Carina Pizzarossa, Gonzalo Silveira, Federico Zazzetti, Ashley Orillion, Urbano Sbarigia, Graciela Alarcon, Bernardo Pons-Estel, Guillermo Pons-Estel
This document will be available on June 11 2025
From Onset to Insights: Longitudinal Assessment of Disease Activity, Flares, and Damage Accrual in Patients with SLE Across 5 Registries in the Lupus Federated Data Network (LupusNet)
Federico Zazzetti, Ashley Orillion, Urbano Sbarigia, Anna Sheahan, Clair Blacketer, Michel van Speybroeck, Sarah Gasman, Reyhan Sonmez, Manuel F. Ugarte-Gil, Rocio V. Gamboa-Cardenas, Victor Pimentel-Quiroz, Guillermo J. Pons-Estel, Rosana Quintana, Verónica Saurit, Cecilia Nora Pisoni, Odirlei Andre Monticielo, Francinne Machado Ribeiro, Jorge A. Esquivel-Valerio, Carlos Núñez Álvarez, Katiuzka Zuñiga, Martin Rebella, Kaleb Michaud, Patricia Katz, Rangi Kandane-Rathnayake, Eric Morand, Worawit Louthrenoo, Alberta Hoi, Mandana Nikpour, Sandra Navarra, Chak Sing Lau, Shue Fen Luo, Laniyati Hamijoyo, Iñigo Rúa-Figueroa, Zulema Plaza, María Galindo-Izquierdo, Julia Martínez-Barrio, Jaime Calvo Alén, Antonio Fernández-Nebro, Raúl Menor Almagro, Javier Narváez, Chetan S. Karyekar
This document will be available on June 11 2025
Icotrokinra, a First-in-Class, Targeted Oral Peptide, in Patients with Psoriatic Disease: Exploratory Assessments From a Phase 2 Psoriasis Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis
Joseph F. Merola, Philip J. Mease, Laura C. Coates, Iain B. McInnes, Peter Nash, Alexis Ogdie, Lihi Eder, Mitsumasa Kishimoto, Anna Beutler, Konstantina Psachoulia, Shihong Sheng, Bei Zhou, Mehrdad Javidi, Chandni Valiathan, Charles Iaconangelo, Ya-Wen Yang, Arun Kannan, Chetan S. Karyekar, Tasneam Shagroni
This document will be available on June 11 2025
Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23-Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-Blind, Placebo-Controlled ICONIC-LEAD Trial
Robert Bissonnette, Jennifer Soung, Adelaide Hebert, Andrew E. Pink, Andreas Pinter, Yuling Shi, Joseph F. Merola, Megan Miller, Joseph Cafone, Jing Zhi (Gigi) Jiang, Cynthia DeKlotz, Mark G. Lebwohl
This document will be available on June 11 2025
Identification of Tissue-Associated Remodeling Endotypes in Rheumatic Disease Cohorts
Rikke Malmkvist, Anne-Christine Bay-Jensen, Dovile Sinkeviciute, Signe H. Nielsen, Morten Karsdal, Monica T. Hannani, Peder Frederiksen, Sheng Gao, Warner Chen
This document will be available on June 11 2025
Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis
Alexis Ogdie, Philip Mease, Francois Nantel, Frederic Lavie, Mohamed Sharaf, Emmanouil Rampakakis, Helena Marzo-Ortega, Laure Gossec
This document will be available on June 11 2025
Inhibition of Structural Damage Progression With Guselkumab, a Selective IL-23i, in Participants With Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde
This document will be available on June 11 2025
Observed and Simulated Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Fully Human FcRn Blocking Monoclonal Antibody, in Adults with Sjögren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study
Sophia G. Liva, Fudan Zheng, Jocelyn H. Leu, Kathy Sivils, Keying Ma, He Li, Jacques-Eric Gottenberg, Steven Leonardo, Kim Hung Lo, Jada Idokogi, Kim Campbell, Jonathan J. Hubbard
This document will be available on June 11 2025
One Year Persistence and Effectiveness of Guselkumab or TNFi as Second-Line Treatment After Receiving a TNFi as First-Line Therapy to Treat Active Psoriatic Arthritis: Manhattan Study
Beatriz Joven-Ibáñez, Maria Rocio Gonzalez Molina, María Vanesa Hernández Hernández, Marta Llanes, Carolina Marin-Huertas, Lourdes Mateo, Elena Alonso Morales, Laura Nuño, Meritxell Sallés Lizarzaburu, Manuel Moreno, Martina Steiner, Antonio Fernández-Nebro, Elisabet Garcia Casares, Angeles Hernandez Del Rio, Janire Malave Calzada, Lola Fernandez De La Fuente Burson, Laia Orpinell, Raúl Veroz González, Evelin Cecilia Cervantes Pérez, Sonia Castro Oreiro, Ana Urruticoechea-Arana, Inmaculada Ros, Patricia López Viejo, Oscar Camacho, Emilio Giner, Luis Sarabia De Ardanaz, Alba Erra, Maria Delpuerto Moreno Gil, Francisco Maceiras-Pan, Jorge Cabezon Dominguez, Daniel Pielfort, Manuel Cuervas-Mons, Sabela Díaz-Castroverde Vicario, Santiago Munoz-Fernández, Julio Ramirez, Jose Antonio Pinto Tasende
This document will be available on June 11 2025
On-Label Persistence Through 24 Months Among Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous TNF Inhibitors
Philip J. Mease, Jessica Walsh, Timothy P. Fitzgerald, Soumya D. Chakravarty, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Linda Hou, Shikha Singla, Joseph F. Merola
This document will be available on June 11 2025
Pharmacodynamic Effects of Nipocalimab on Disease Biomarkers in Patients with Moderate-to-Severe Active Sjögren's Disease: Results from a Multicenter, Randomized, Double-Blinded, Placebo-controlled Phase 2 Study
Kathy L. Sivils, Steven Leonardo, He Li, Keying Ma, Jacques-Eric Gottenberg, Matthew J. Loza, Jonathan J. Hubbard, Kim Campbell, Sheng Gao
This document will be available on June 11 2025
Pharmacodynamic Response of JNJ-77242113 in Serum and Skin of Patients with Moderate-to-Severe Psoriasis: 1-Year Results from FRONTIER 1 & 2
Kilian Eyerich, Laura K. Ferris, James Krueger, Amy Paller, Andreas Pinter, Arun Kannan, David Strawn, Sunita Bhagat, Dylan Richards, Daniel Horowitz, Kate Paget, Ching-Heng Chou, Joseph F. Merola, Elizabeth Chen, Cynthia DeKlotz, Paul Newbold, Dawn Waterworth, Monica Leung, Bradford McRae, Megan Miller, Takayuki Ota, Darren Ruane, Ya-Wen Yang, Robert Bissonnette
This document will be available on June 11 2025
Safety, Tolerability, and Activity of JNJ-67484703 in Participants with Active Rheumatoid Arthritis: Results of a Multicenter, Double-blind, Placebo-controlled, Randomized, Multiple-dose Phase 1b Study
Irving T.C. Ling, Stanley J. Marciniak, Stephen Clarke, Vani Lakshminarayanan, Matthew J. Loza, Sophia G. Liva, Tong Wang, Ashley Orillion, Ilia Tikhonov, Erika H. Noss
This document will be available on June 11 2025
The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus
Guillermo Pons-Estel, Rosana Quintana, Romina Nieto, Hermine Brunner, Marina Scolnik, Carmen Funes Soaje, Paula Alba, Verónica Saurit, Mercedes Argentina Garcia, Guillermo A. Berbotto, Verónica Bellomio, Eduardo Mario Kerzberg, Graciela Noemí Gómez, Cecilia Nora Pisoni, Vicente Juárez, Ana Malvar, Nilzio Antonio da Silva, Odirlei Andre Monticielo, Henrique Ataide Mariz, Francinne Machado Ribeiro, Eduardo F. Borba, Eloisa Bonfa, Edgard Torres dos Reis-Neto, Iris Guerra Herrera, Loreto Massardo, Gustavo Aroca Martínez, Lorena Gómez Escorcia, Carlos A. Cañas, Gerardo Quintana-Lopez, Carlos Enrique Toro Gutiérrez, Mario Javier Moreno Alvarez, Miguel Ángel Saavedra, Margarita Portela Hernández, Fragoso-Loyo Hilda, Luis H. Silveira, Ignacio García de la Torre, Carlos Abud-Mendoza, Jorge A. Esquivel Valerio, María Isabel Acosta, Astrid Paats, Claudia Mora-Trujillo, Manuel F. Ugarte-Gil, Armando Calvo Quiroz, Roberto Muñoz Louis, Martín Rebella, Álvaro Danza, Federico Zazzetti, Ashley Orillion, Urbano Sbarigia, Bernardo Pons-Estel
This document will be available on June 11 2025
Treatment of Plaque Psoriasis Involving High-Impact Areas with Icotrokinra, a Targeted Oral Peptide That Selectively Binds the Interleukin-23–Receptor: Results Through Week 16 of the Phase 3, Randomized, Double-blind, Placebo-Controlled ICONIC-TOTAL Trial
Melinda Gooderham, Edward (Ted) Lain, Robert Bissonnette, Yu-Huei (Julia) Huang, Charles Lynde, Matthias Hoffmann, Joseph F. Merola, Eingun James Song, Jessica H. Rubens, Amy M. DeLozier, Ming-Chun Hsu, Richard B. Warren
This document will be available on June 11 2025
Validation and Characterization of Six Distinct SLE Molecular Subtypes Using Two Large Patient Cohorts and Multi-Omics Platforms
Loqmane Seridi, Eugene Myshkin, Erika Noss, Dawn Waterworth, Matthew J. Loza, Sheng Gao
This document will be available on June 11 2025
VISIBLE: Guselkumab Impact on Psoriatic Arthritis at Week 16 in Participants With Moderate to Severe Psoriasis Across All Skin Tones
Alice B. Gottlieb, Amy McMichael, Tina Bhutani, Olivia Choi, Theodore Alkousakis, Jenny Jeyarajah, Donna Febres, Oyediran Adelakun, Soumya D. Chakravarty, Daphne Chan, Joseph F. Merola
This document will be available on June 11 2025
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.